PainReform falls after pain relief treatment fails late-stage trial

PRF Technologies

27/12/2024 14:18

** U.S.-listed shares of Israel based drug developer
PainReform  PRFX.O  fall 18.4% to $4 premarket 
    ** Co says its lead experimental pain relief treatment,
PRF-110, did not meet the main goal of a late-stage study 
    ** Co announced interim data from the late-stage study in
November where it was testing PRF-110 to study the effect of the
treatment in reducing pain over 72 hours  
     ** Co had previously said that data from the late-stage
pertaining to the last 24-hour period of the 72-hour study was
unclear  
    ** After further investigation co says the data could not be
clarified to satisfy the study's main goal 
    ** Co says despite setback, it has started R&D activities to
better understand the effects of the treatment "to potentially
resolve this issue to support future clinical trials"
    ** PRF-110 was tested to provide prolonged pain relief while
reducing the need for opioids, in the post-surgical setting
    ** Up to last close, stock down 92.6% YTD 

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))